Cantor Fitzgerald initiated coverage on Poseida Therapeutics with a new price target

1/7/22 8:13:46 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Cantor Fitzgerald initiated coverage of Poseida Therapeutics with a rating of Overweight and set a new price target of $24.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PSTX

Date	Price Target	Rating	Analyst
12/2/2024	$10.00	Overweight → Neutral	Piper Sandler
1/4/2023	$15.00	Buy	H.C. Wainwright
1/7/2022	$24.00	Overweight	Cantor Fitzgerald